Aim: Anxiety is a common presenting concern for individuals at clinical high risk (CHR) for psychosis. Treatment for CHR is still in the early stages and has focused on transition to psychosis and positive symptom reduction, but little is known about what may be effective in reducing anxiety for these young people. One treatment that may be effective for anxiety is heart rate variability (HRV) biofeedback. The aim of this study was to test the efficacy and feasibility of using HRV biofeedback to reduce anxiety and distress in those at CHR.
Methods: Twenty participants who met minimum scores for anxiety and distress completed 4 weeks of an HRV biofeedback intervention and received pre-and post-intervention assessments. Repeated measures were used to examine changes in scores over time.
Results: There was a significant decrease in impaired ability to tolerate normal stressors (P ≤ 0.001) and dysphoric mood (P ≤ 0.001) over time. There was no change on self-reported measures of anxiety and distress. However, when two outliers were removed there was a trend towards improvement in self-reported anxiety (P = 0.07). These results were not impacted by including usage time as a covariate. Feedback and adherence were significant.
Conclusions: HRV biofeedback may be a feasible treatment option for individuals at CHR who have concerns with impaired stress tolerance and dysphoric mood. Future studies with a randomized controlled trial design will be necessary to further determine efficacy.
INTRODUCTION
Anxiety has been identified as a frequent concern in schizophrenia. [1] [2] [3] It can contribute to distress and negatively impacts functioning and quality of life. 1, 4 Similarly, a substantial number of individuals at clinical high risk (CHR) for psychosis present with anxiety disorders 5 and distress. 6 In fact, in CHR, anxiety and depression are most frequently endorsed as the first noticed symptoms 7 and are often of more concern to these individuals than their sub-threshold psychotic symptoms. 8 Up to half of CHR individuals meet diagnostic criteria for an anxiety disorder 9 and they frequently have an impaired ability to tolerate normal stress. 10 There are several interventions used for anxiety, such as pharmacological approaches, cognitive behavioural therapy (CBT), 11 biofeedback, 12 exposure-based interventions, 13 exercise, 14 progressive muscle relaxation, yoga, mindfulness, hypnotherapy, meditation and nutritional changes. 15 Treatments demonstrating efficacy in schizophrenia include CBT, 16 second-generation antipsychotics and selective serotonin reuptake inhibitor (SSRI), exposure-based therapies, progressive muscle relaxation, yoga and mindfulness. 1, 17 Several treatment approaches for individuals at CHR are being explored including CBT, [18] [19] [20] [21] [22] antipsychotic medication [23] [24] [25] and omega-3 supplements 26 for reduction of transition rates and positive symptoms. However, anxiety reduction has not been a primary outcome. Studies that did report on anxiety did not observe reduced anxiety with CBT versus the control condition, 20, 22 although one study found that improvement in anxiety was observed in both their CBT and supportive therapy groups. 18 As one of the most common presenting concerns for young people at CHR, anxiety is a valuable treatment objective. One treatment that has not been explored in this population is heart rate variability (HRV) biofeedback.
The heart is dually innervated by the sympathetic and parasympathetic nervous systems, 27 allowing for processes of the heart to provide an index for autonomic functioning. HRV reflects beat-to-beat changes in heart rate and provides a measure of neurological ability to function adaptively within changing environments. 28 Thus, higher variation indicates an increased ability to respond to external demands and changes. Low HRV indicates increased sympathetic nervous system activity 29 and is characteristic of many psychiatric and general medical conditions. 12 There is evidence for autonomic system dysfunction as evaluated by low HRV, low vagal activity and poor autonomic adaptability and reactivity in people with schizophrenia. [30] [31] [32] [33] This is similarly observed in anxiety disorders, although more pronounced in psychosis. 34 A simple and non-invasive way to impact autonomic activity is with HRV biofeedback, a tool that can increase HRV, mainly through the regulation of breathing in response to external feedback to influence associated autonomic reactions. 35 There is evidence for reduced symptomatology in a variety of illnesses, including anxiety disorders, through increasing HRV with biofeedback. 12 In summary, treatments are needed not only to prevent or delay the development of psychosis but also to address the significant associated symptomatology, such as anxiety, experienced by young people at CHR. The aim of this study is to examine the efficacy and feasibility of an HRV biofeedback intervention to target anxiety and distress in young people at CHR. It is hypothesized that CHR individuals with repeated exposure to HRV biofeedback will demonstrate improvements in (i) measures of anxiety; (ii) distress scores and (iii) the symptoms of impaired tolerance to normal stress and dysphoric mood on the Scale of Prodromal Symptoms (SOPS).
METHODS

Study design
This study was an open 4-week trial using a singlegroup pre-and post-test design to evaluate HRV biofeedback. An open-trial design was chosen as this was a pilot study to inform feasibility, possible efficacy and effect sizes for a larger study.
Sample
Twenty participants (6 males and 14 females) were recruited for this study. All participants met CHR for psychosis criteria according to the Criteria of Prodromal Syndromes (COPS), which is based on the Structured Interview for Prodromal Syndromes (SIPS). 36 Gold standard post-training agreement on determining the prodromal diagnoses was significant (k = 0.90). 37 All participants either (i) had a raw score of 36 or higher on the Self-Rating Anxiety Scale (SAS) 38 and/or (ii) scored 20 or higher on the Kessler Psychological Distress Scale (K10). 39 Participants were excluded if there was a known history of a cardiac illness, known hypothyroidism/hyperthyroidism or an initiation or change in dose of psychiatric medication within the month prior to baseline assessment. Exclusion criteria also included: having a current or lifetime Axis I psychotic disorder, impaired intellectual functioning (intelligence quotient < 70), past or current clinically significant central nervous system disorder, substance dependence in the past 6 months or if the diagnostic prodromal symptoms were clearly caused by an Axis I disorder, including substance-use disorders, in the judgement of the evaluating clinician.
Measures
The Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) Disorders 40 was used to determine the presence of major DSM-IV Axis I disorders and to rule out any psychotic disorders and the SIPS and the SOPS 36 to determine COPS criteria and symptom severity. The items 'dysphoric mood' and 'impaired tolerance to normal stress' from the general symptoms of the SOPS were outcome measures for this study. The K10 39 measured distress related to anxiety and depressive symptoms. A score of 20 or above may indicate between a mild and severe mental disorder. The Social Interaction Anxiety Scale (SIAS) 41 measures anxiety in social situations and the Zung SAS 38 measured general anxiety. A raw score of 20-36 is considered to be within the normal range and higher scores indicate between mild and extreme anxiety. Social and Global Functioning Scales 42 were specifically designed for use with those at CHR.
Procedures
Raters were experienced research clinicians who demonstrated significant reliability at routine reliability checks. The study protocols and informed consents were approved by the local ethics committee. All participants provided informed consent or assent prior to completing study measures and parental or guardian consent was also obtained for participants under age 18 years.
After completing the baseline assessment, participants received anxiety education to provide a rationale for the intervention and to help compliance. They were then given the biofeedback device and instructions for use. Biofeedback was achieved using emWave ® 2 technology developed by the Institute of HeartMath (Boulder Creek, CA, USA). Participants received both a hand-held biofeedback device and computer software and were taught to pace their breathing in accordance with the light and sound feedback from the device. The small, portable device can be used alone, or with the computer software that provided interactive games. This technology provides an online platform that uploads session data, so that actual usage can be determined. Participants were directed to use the biofeedback intervention a minimum of 1 hour per week for 4 weeks. Exposure time was based on averages taken from previous studies, which were variable. [43] [44] [45] [46] [47] [48] Participants were contacted weekly to check on usage, questions or concerns. Every effort was made to ensure that each participant received the same amount of contact.
At the end of the 4-week intervention, participants returned the biofeedback device and completed the outcome measures. Participants then completed a follow-up 4 weeks after the end of intervention visit. To protect against sources of bias, those responsible for monitoring and supervising the treatment were not involved in follow-up assessments.
Statistical analysis
All outcome variables were examined prior to analysis for distribution and all variables were normally distributed on measures of skewness and kurtosis except for the item grandiose ideas. Repeated measures with Sidak post hoc tests were used, as Mauchley's test of sphericity was not significant, to examine changes in Impaired Tolerance to Normal Stress, Dysphoric Mood, SAS, K10, SIAS, SOPS and functioning scores over the three visits: baseline, week 4 and end of study follow-up. Biofeedback usage time was then added as a covariate to the repeated measures to control for a dose response.
RESULTS
Recruitment
Out of 20 participants enrolled in the study, 12 met entry criteria for both the SAS and K10 and eight participants met only K10 criteria. One participant was lost to follow-up and was unable to be contacted after baseline. An additional two participants declined to complete the end of study follow-up assessment (see Fig. 1 ).
Participant characteristics
Mean age of participants was 16.70 years (standard deviation (SD) = 2.30, range = 13-22). The majority of participants were female, Caucasian, never married, living with their family and currently enrolled as a student. Out of the 20 participants enrolled in the study, 18 met CHR criteria based on attenuated positive symptoms and two met for genetic risk and deterioration. The majority of participants met criteria for an anxiety and/or a depressive disorder (see Table 1 ).
Mean scores of SOPS and functioning are presented in Table 2 . Repeated measures were conducted to determine if there was any change over time. There were significant decreases in unusual thought content, grandiose ideas and total positive symptom scores.
Other treatment
At study entry, several participants were receiving concurrent pharmacological or psychological treatment. Details are presented in Table 3 . One participant was an inpatient on a psychiatric unit at study entry and received passes to complete study assessments. Another participant was hospitalized after their week 4 assessment due to suicidal ideation and depression and was discharged prior to end of study follow-up.
Adherence
Participants were instructed to use the biofeedback for a minimum of 1 hour per week, or 240 min in total. Adherence varied and ranged from 5 to 486 min. The mean amount of usage time was 142 min. Twenty percent of participants used the biofeedback for 4 hours or more, an additional 25% used it for more than 2, 25% used it for between 1 and 2 hours and 30% used it for <1 hour. Average use was 48 min during week 1, which steadily decreased to 23 min by week 4. Several participants reported that they wished they had used it more and cited avolition as a barrier.
Outcome
There was a significant change over time on impaired tolerance to normal stress and dysphoric mood. There was no significant change over time on the K10, SAS or SIAS self-reported measures (see Table 4 ). Usage time was added as a covariate to the repeated measures. However, this had no impact on these results. Two participants had a noticeable worsening in SAS scores. One of these participants had increasing depression with suicidal ideation and was hospitalized during the study. The other used the biofeedback for a total of 7 min and was 5 weeks late for their week 4 assessment. When these outliers were removed, there was a trend for improvement in SAS scores (F = 2.86, P = 0.07).
Participant's feedback
Participant's feedback was positive with 85% of participants reporting that they were moderately to very satisfied with the study. No participants reported dissatisfaction. Participants reported that the biofeedback was moderately to very easy to use and somewhat to moderately helpful with anxiety. A few participants reported finding it most useful for panic attacks, stressful situations or anger.
DISCUSSION
This pilot study examined the utility of an HRV biofeedback intervention for young people at CHR for psychosis who reported experiencing anxiety and distress. Our first two hypotheses, that there would be improvements in anxiety scores and distress scores, were not supported as there were no significant changes on the SAS, SIAS or K10 measures of anxiety and distress. However, there was support for the third hypothesis as the two SOPS items, impaired stress tolerance and dysphoria, significantly improved.
There are several possibilities for the lack of change on the self-reported measures. First, the study was underpowered and the sample size was too small to detect a difference or to handle outliers. Second, it is possible that 4 weeks was not a sufficient length of time, although several studies in non-CHR anxiety populations did observe an effect with this duration of time or less. 44, 46, 47, 49 However, increasing duration may not be advantageous as participants were most adherent during the first week with a steady decline through the subsequent 3 weeks. Despite our observation that there was no dose effect, only 20% of participants used the biofeedback for the recommended amount of time and as a result exposure time may have been inadequate. Third, HRV biofeedback primarily targets autonomic responses but it may be difficult to impact anxiety and distress if other factors are not addressed, such as underlying thoughts. Thus, it may be more effective to add HRV biofeedback as an adjunctive therapy. The potential for increased treatment efficacy by using combination therapy for anxiety is supported in the literature, such as CBT plus an SSRI. 50 Although many individuals were receiving concurrent treatments in this study, these varied widely. Thus, it would be useful to examine HRV biofeedback as an adjunct to other treatments where these treatments are administered consistently for all participants.
Finally, it may have been problematic using the SIAS which measures social anxiety and was included because social phobia is one of the most prominent anxiety disorders in CHR. However, it has been suggested that social anxiety may not respond well to 'generic' anxiety disorder treatment in children and adolescents and may need intervention specific to social interactions, such as social skills training or increasing opportunity for peer interaction. 11 Other studies have found CBT and pharmacological approaches to be the most efficacious in treating social anxiety. 51, 52 To the best of our knowledge, HRV biofeedback has not been examined for the treatment of social phobia. Furthermore, as participants did not use the intervention in social situations, an impact on the behavioural and cognitive items of the SIAS is unlikely because these are not the target mechanisms of change from HRV biofeedback.
There was however both clinically and statistically significant decreases in both impaired tolerance to normal stress and dysphoric mood. Impaired tolerance to normal stress averaged moderate-moderately severe at baseline, indicating increasing difficulty with daily experiences that previously were easily dealt with but are currently becoming very challenging. By week 4, this item was on average rated at a mild level and remained stable until the end of the study. Dysphoric mood averaged moderately severe at baseline, indicating recurring periods of anxiety, sadness, irritability and depression. This item decreased to a moderate level by week 4 and even more to mild-moderate by the end of the study. These reductions may indicate that participants' ability to cope and the degree to which they are impacted by anxiety and distress significantly improved during the intervention.
There was a significant reduction in positive symptoms on the SOPS. Symptoms decreased an average of one point for overall positive symptom scores and unusual thought content. However, the mean average at baseline was slightly below a level of three, which is below the threshold for COPS criteria. Therefore, although this decrease is statistically significant it may not be clinically significant.
Although there was variation in levels of adherence to the required usage time, the majority of participants had at least 1 hour of exposure to the HRV biofeedback intervention. Adherence was not found to impact changes in scores but overall the adherence does suggest that participants were willing to use the intervention on a repeated basis. Participant's feedback was also positive with the majority reporting high levels of satisfaction with their study experience. Taken together, observed improvements in scores, adherence and participant's feedback indicate that this type of intervention is well-tolerated and may be a feasible option for individuals at CHR who are experiencing anxiety and distress.
There are several limitations to this study. First, the use of a single-group pre-and post-test design, rather than a randomized controlled trial design, limits the ability to determine if any effects observed were due to the intervention. Second, the study was likely underpowered as the sample was small. Sample size was based on the fact that individual devices had to be purchased and this first trial was intended to be a feasibility study. Third, many individuals were receiving concurrent treatment during this study that may have impacted scores of anxiety and distress. However, we attempted to reduce the impact of psychotropic medications as a confounding variable by excluding those who had changes in their treatment within the last month from this study, although several participants had treatment changes after beginning the study. This study did not control for substances such as alcohol, caffeine or nicotine. Fourth, the use of self-reported measures increases the possibility of reporting biases, although ratercompleted measures were also used for outcome. Fifth, participants used the biofeedback on their own time and this may have impacted adherence, although this was done in order to provide a more real-world understanding of usage and to reduce additional beneficial effects of repeated therapeutic contact. Furthermore, HRV data was not measured in this study, so it is not possible to determine if the biofeedback impacted HRV. Finally, it is possible that the treatment was not efficacious, although the lack of power also impacts this conclusion.
This study has clinical implications for the treatment of individuals at CHR for psychosis. Anxiety is a common concern for these young people and HRV biofeedback may be a useful tool to alleviate impaired stress tolerance and dysphoria. It may be best utilized as an adjunct to other interventions with well-established efficacy for anxiety, such as CBT. HRV biofeedback could be useful in situations where other relaxation or stress reduction techniques, such as mindfulness, meditation and physical activity, are often recommended. 53 HRV biofeedback may be specifically advantageous in certain situations, such as where the use of an interactive technology may be more engaging with younger people than other relaxation techniques. Future steps for determining the efficacy of HRV biofeedback for anxiety in the CHR population would be a randomized controlled trial with an adequately powered sample controlling for confounding variables, such as concurrent treatment and including pre-and post-measures of HRV. A larger sample would allow for the comparison of completers versus non-completers.
In conclusion, this pilot study demonstrated that HRV biofeedback is a well-tolerated intervention that may be useful in reducing some presenting symptoms of concern, such as impaired stress tolerance and dysphoric mood, in individuals at CHR experiencing anxiety and distress. Thus, HRV biofeedback may be a feasible treatment option for young people at CHR for psychosis.
